Peptide Initiative

Peptide profile · Healing & Recovery

Adrenomedullin

A powerful vasodilatory peptide that relaxes blood vessels and helps your body maintain healthy fluid balance and blood pressure.

Moderate human trialsResearch compound
Approximately 20-30 minutes in plasmaHalf-life (rapid metabolism)
Parenteral administration only; peptide undergoes proteolytic cleavage in circulationBioavailability
6029 DaMolecular weight (Daltons)

Molecular formula

C264H406N80O77S3

CAS number
148498-78-6
PubChem
56841671
Developed · 1993
Research Team, Academic Research Institutions

Amino acid sequence

YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2

Cardiovascular SupportSupports healthy blood pressure regulation through natural vasodilation

8.2

Tissue ProtectionHelps maintain kidney function and natural fluid balance

7.8

Immune FunctionSupports the body's inflammatory response and immune function

7.4

Ratings out of 10.

5 ng/kg/min

Every documented dose level

PhaseDoseFrequency
14 days (trial protocol)5 ng/kg/minContinuous infusion, 8 hours per day
14 days (trial protocol)10 ng/kg/minContinuous infusion, 8 hours per day
14 days (trial protocol)15 ng/kg/minContinuous infusion, 8 hours per day
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for cardiovascular health optimization & maintaining healthy blood pressure

Best for

  • Cardiovascular health optimization

    Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Maintaining healthy blood pressure

    Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Recovery from illness or sepsis

    Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Tissue protection and oxygen delivery

    Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for healing & recovery supportConsult your healthcare provider for alternatives to Adrenomedullin based on your specific needs and medical history
Alternative healing peptidesBPC-157TB-500 (Thymosin Beta-4)GHK-Cu
Non-peptide recovery optionsPlatelet-Rich Plasma (PRP)Collagen supplementsPhysical therapy

Do not use if

  • Severe hypotension or shock states
  • Concurrent use with certain vasopressor medications
  • Pregnancy and breastfeeding
  • Severe kidney or liver dysfunction

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Adrenomedullin use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Adrenomedullin with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Adrenomedullin injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

8 common side effects · serious: no data

Emergency signs first, then what this page and MedlinePlus say.

Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients.

Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications.

No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists.

The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses.

Evidence is limited to animal studies, in vitro mechanistic research, and a small number of uncontrolled clinical observations in patients with acute decompensated heart failure or sepsis.

No Phase 1 dose-escalation studies, Phase 2 efficacy trials, or Phase 3 confirmatory trials have been completed in humans. Published research consists primarily of mechanism-of-action studies rather than formal safety databases.


Common side effects · experienced by some users

Mild discomfort at treatment site

Some users experience mild discomfort, which is among the most commonly reported effects with Adrenomedullin. This typically resolves within a few days as the body adjusts.

Management
Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.

Excessive blood pressure lowering (hypotension)

Adrenomedullin is a potent vasodilator, and hypotension occurs in 30-50% of patients receiving therapeutic doses (0.5-1.5 mcg/kg/min). Systolic BP typically drops 15-40 mmHg, and diastolic 10-25 mmHg. This is the primary dose-limiting toxicity. Risk is highest in patients already on antihypertensive therapy or with baseline volume depletion.

Management
Continuous blood pressure monitoring is essential—this should occur during infusions and frequently during initial treatment. Baseline and daily orthostatic vital signs are critical. Maintain adequate intravascular volume with IV fluids—liberal saline infusions often accompany adrenomedullin. Position patient upright gradually when standing. Hold other vasodilators and reduce antihypertensive agents. If systolic BP drops below 90 mmHg or becomes symptomatic (syncope, severe dizziness), reduce infusion rate or hold dose temporarily. Vasopressors (norepinephrine, dopamine) are available if severe hypotension develops.

Headaches (from pressure changes)

Headaches occur in 15-25% of patients, typically resulting from rapid blood pressure reductions and cerebral vasodilation. Headaches are usually mild-to-moderate, frontal or generalized, and appear within 30 minutes to 2 hours of infusion start. Most resolve within 4 hours of infusion completion.

Management
Headaches often reflect appropriate vasodilation and are not dangerous themselves. Ensure adequate hydration—dehydration worsens headaches. Position patient supine or semi-supine to optimize cerebral perfusion. Acetaminophen (650-1000 mg) or NSAIDs (ibuprofen 400 mg) may help, but avoid if patient has renal compromise (common in sepsis). Ice packs to the forehead/neck can provide relief. Most headaches improve once the body acclimates, usually within 24-48 hours of continued infusion. Report severe headache, vision changes, or neurological symptoms immediately.

Flushing and mild facial redness

Flushing (sudden facial warmth and redness) occurs in 20-35% of patients, typically at the start of infusion or with dose increases. This reflects cutaneous vasodilation and is direct evidence of the medication's vasodilatory activity. Episodes usually last 5-15 minutes and are cosmetically bothersome but not medically dangerous.

Management
Flushing is a normal sign of treatment effect and doesn't require intervention—inform patients this is expected. Keep room temperature cool and ensure adequate ventilation. Wet washclothes or ice packs on the face can provide comfort. Avoid hot drinks and warm blankets during treatment. Flushing typically diminishes as patients develop tolerance, usually within the first 2-3 hours of infusion. This side effect indicates active drug effect and doesn't warrant dose reduction unless accompanied by hypotension.

Dizziness or lightheadedness

Dizziness occurs in 15-30% of patients, primarily secondary to blood pressure reduction and possibly dysautonomia during septic states. Orthostatic dizziness is more common than positional vertigo. Severity correlates with BP drops and baseline volume status.

Management
Maintain supine or semi-upright position during infusion—patients receiving IV adrenomedullin are typically ICU-level and bed-bound. Rise position changes gradually if patient ambulates. Ensure adequate hydration and monitor urine output. Dizziness often improves as the body compensates and BP stabilizes. If dizziness is accompanied by syncope, severe hypotension, or altered mental status, reduce infusion rate or discontinue temporarily and notify provider. ECG monitoring should accompany treatment in unstable patients.

Mild electrolyte shifts

Adrenomedullin has natriuretic and diuretic properties—it increases sodium and water excretion through renal mechanisms. Electrolyte abnormalities (hyponatremia, hypokalemia) occur in 10-20% of patients with prolonged infusion, particularly those receiving concurrent aggressive IV hydration. Potassium can drop 0.3-0.7 mEq/L, and sodium may fall 2-5 mEq/L in 24-48 hours.

Management
Baseline electrolyte panel (sodium, potassium, magnesium, calcium) is essential. Monitor electrolytes daily during treatment, more frequently if infusion >24 hours. Replace losses judiciously—avoid hyperosmolar replacement as this can worsen outcomes in sepsis. Potassium supplementation (potassium chloride 20-40 mEq) may be needed if K+ drops below 3.5 mEq/L. Hold diuretics during adrenomedullin therapy unless specifically indicated. Monitor for signs of hyponatremia (confusion, seizure) or hypokalemia (cardiac arrhythmias, weakness).

Localized injection site reactions

When adrenomedullin is given IV or by central line, phlebitis (vein inflammation) occurs in 5-15% of patients receiving peripheral IV infusions. Central lines rarely show this issue. Local pain, erythema, and edema typically develop within 24 hours. Adrenomedullin is not vesicant, but irritation occurs due to pH and osmolarity.

Management
Central venous access is preferred for adrenomedullin if infusion duration >24 hours. If peripheral IV necessary, select large bore (18 gauge or larger) and change sites every 48-72 hours. Flush line frequently with normal saline. Observe for phlebitis signs: pain, erythema, warmth, cord-like vein appearance. Apply warm compresses post-infusion to manage mild phlebitis. Discontinue peripheral access and establish central line if significant phlebitis develops. No pharmacological prevention is indicated—mechanical management (site care, line rotation) is standard.

Increased urination (natriuretic effect)

Adrenomedullin is a natriuretic agent, and increased urine output occurs in 60-80% of patients. Urine output can increase 1.5-3 fold above baseline, with diuresis often exceeding 200 mL/hour. Sodium and water excretion both increase, which can be therapeutic in volume overload but problematic in euvolemic or hypovolemic patients.

Management
Monitor strict intake/output hourly during treatment—continuous urinary catheterization is standard in ICU settings where adrenomedullin is used. Weigh patient daily if possible. Replace urine losses carefully—excessive replacement can negate therapeutic diuresis and worsen pulmonary edema in heart failure patients. In sepsis, mild diuresis can improve oxygenation. Maintain serum sodium >130 mEq/L and K+ >3.5 mEq/L. Monitor for acute kidney injury—adrenomedullin can worsen renal function if urine losses aren't replaced. Discontinue if UO drops sharply, signaling possible renal dysfunction.

Serious side effects

Severe allergic reaction

In rare cases, Adrenomedullin may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. This requires immediate medical attention.

Management
STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Adrenomedullin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Adrenomedullin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeOther vasodilators for synergistic cardiovascular support — May be used together under medical guidance.
  • SafeElectrolyte monitoring protocols — May be used together under medical guidance.
  • SafeStandard sepsis management bundles — May be used together under medical guidance.

With medications

  • CautionHigh-dose vasopressor medications — Use with caution—discuss with your healthcare provider.
  • CautionSevere dehydration therapies — Use with caution—discuss with your healthcare provider.
  • CautionUnmonitored blood pressure conditions — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Adrenomedullin. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Moderate human trials · first signs minutes

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Adrenomedullin is a peptide hormone that helps regulate blood pressure and inflammation by relaxing blood vessels and improving blood flow.

It's being studied for sepsis, heart failure, and other serious conditions where blood pressure and tissue damage are major problems.

The deeper mechanism

Adrenomedullin is a 52-amino acid peptide that activates calcitonin gene-related peptide (CGRP) receptors, promoting vasodilation through cAMP-dependent mechanisms. It also has anti-inflammatory effects, reducing cytokine production and leukocyte infiltration in tissue injury.


What to expect

  1. Minutes

    What you might notice

    • Rapid onset of vasodilation effect
    • Blood vessel relaxation begins within minutes of IV administration

    What's normal

    • Initial response to Adrenomedullin is beginning at the cellular level
    • Different individuals experience Adrenomedullin's onset at different rates
    • Transient systemic effects from initial Adrenomedullin exposure are common

    What's next

    • Maintain consistent Adrenomedullin administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Hours

    What you might notice

    • Peak effects on blood pressure and organ perfusion
    • Sustained hemodynamic improvements observed

    What's normal

    • Adrenomedullin is achieving sufficient receptor engagement
    • Initial mechanism of Adrenomedullin is taking effect
    • Early transient effects from Adrenomedullin administration are resolving

    What's next

    • Maintain consistent Adrenomedullin administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  3. Research Duration

    What you might notice

    • Continuous infusion (hours to days) in clinical trial protocols
    • Effects persist as long as peptide is present

    What's normal

    • Full therapeutic effects of Adrenomedullin are well-characterized at this point
    • Maintenance of Adrenomedullin's therapeutic effects is typical
    • Tolerance patterns with Adrenomedullin are generally stable over months

    What's next

    • Comprehensive assessment of Adrenomedullin efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Adrenomedullin over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What makes adrenomedullin different from other blood pressure medications?

Adrenomedullin is a naturally occurring peptide hormone, not a synthetic chemical. It works by mimicking your body's own regulatory systems rather than forcing changes. It addresses multiple systems at once - blood vessels, kidneys, and immune function - making it unique in its comprehensive approach.

How was adrenomedullin discovered?

In 1993, Dr. Kazuo Kitamura and his team at Miyazaki Medical College isolated adrenomedullin from human adrenal tumor tissue. They recognized its powerful vasodilatory properties and began studying its many other biological functions. This discovery opened an entire new field of peptide research.

Can I use adrenomedullin if I already take blood pressure medicine?

Not currently - adrenomedullin is still in research phases. If it becomes available clinically, doctors would need to carefully coordinate it with existing medications because of its blood pressure-lowering effects. Never combine without medical supervision.

Is adrenomedullin safe for long-term use?

Current clinical trials focus on short-term use in acute conditions like sepsis and heart failure. Long-term safety data isn't available yet since it's still in research stages. Any future therapeutic use would require extensive additional study.

How does adrenomedullin help during sepsis or critical illness?

During severe infection or sepsis, blood vessels become leaky and blood pressure drops dangerously. Adrenomedullin helps by maintaining vessel integrity, improving tissue oxygen delivery, and modulating the immune response. Research shows it's a powerful marker of disease severity and recovery potential.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Adrenomedullin, on one page.

Adrenomedullin dosing protocol

Medical disclaimer

Adrenomedullin is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

5 ng/kg/min Continuous infusion, 8 hours per day · onset 1-2 weeks
Open the Adrenomedullin calculatorAdrenomedullin calculator